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technical misjudgments. As difficult as it is to be a Monday
morning Quarter Back or post one-day cricket analysis, this
post PCI complication is further magnified when decisions
were made to use a BVS without clear visibility and wires that
were not clearly separated. Was this complication avoidable
remains to be the question?
As the number of percutaneous coronary interventions are
growing around the world, more outside US currently than in
the USA that was in the lead for past 2 decades, one has to
wonder whether the devices are being used appropriately.1
There is no doubt that stents are vascular scaffolds and
were approved as a therapy to treat dissections and prevent
recoil. The role of stents in the absence of a dissection and an
optimal result with PTCA is not clear. However, as the risk of
bare metal stenting has diminished, direct stenting without
pre-dilation in majority of the lesions has become customary.
The first generation drug eluting stents have opened up dis-
cussions around late and very late stent thrombosis and
duration of DAPT.2 FDA recommends 12 month of DAPT.
Research led to development of thin strut stents, biodegrad-
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vascular scaffolds (BVS) are one such attempt to lower stent
thrombosis. Idea is great. If the foreignmaterial in the vessel is
responsible for stent thrombosis, then inherently a stent that
can resorb and leaves no trace ideally should have no stent
thrombosis.
Thatbringsus to thenextquestion?What is an ideal stent.A
stent that treats dissections, prevents recoil, gets endothe-
lialized or resorbs in a reasonable time period be it 3
monthse12 months. That said, an ideal lesion is a denovo
lesion in a 2.5e4.0 mm vessel excluding left main coronary
artery and in a non-acute setting for which the stents are
approved by US FDA. As the comfort of physicians has grown,
currently stents are used as part of percutaneous coronary
interventions in left main, bifurcations, vein grafts to name a
fewof off-label indications. I recallmy lawsuit in 2006 for using
aCypherdrugeluting stent for a baremetal in-stent restenosis.
Of course, it was dismissed after 2 years by a judge after
listening to expert witnesses that it was off-label but still
within the standard of practice in that region at that time.
As Asia and Europe lead the use of BVS, as professionals,
we have to remind ourselves the original indications andB Scaffold in left main during anomalous LMCA stenting by Pratap
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colleagues in their article bring to attention the importance of
imaging such as optical coherence tomography in BVS im-
plantation. What one perceives as a simple procedure can
have unexpected consequences either acutely or late if
attention has not been paid and only depended on angiog-
raphy. This is a good example of the limitation of angiography.
Imaging is still under utilized in the USAwith about 10e20% of
all PCIs currently. Yes, the complication is avoidable, if the
authors had used only one wire and not used a post-dilating
balloon. However, post dilating a mal-apposed BVS is impor-
tant to improve outcomes. One could argue the use of BVS in
such a scenario, where the risk of stent thrombosis or in-stent
restenosis is very low with a large diameter >4.0 metallic 3rd
or 4th generation stents.
I applaud the authors for coming forward with an article
that raises discussion about appropriate use of BVS, limitation
of angiography, benefits of optical coherence tomography and
ultimate successful revascularization. Thus, Medicine re-
mains as an art and good judgment comes from bad experi-
ences that are due to bad judgment.Conflicts of interest
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